MedTrace Logo

Effect of Symbicort on GR Localisation in Asthma

NCT00159263 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-09-27

Study results available
· View outcomes & findings →

Summary

To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.

Conditions

Interventions

DRUG

Placebos

Dry powder inhaler

DRUG

Formoterol Inhalant Powder

12ug

DRUG

Budesonide Powder

Inhaler

DRUG

Budesonide and Formoterol Product

Combination Inhaler, Symbicort

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sergei A Kharitonov, MD PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159263 on ClinicalTrials.gov